

G1 H,OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO

Structure attributes must be viewed using STN Express query preparation.

=>

=> d ibib abs hitstr 1-4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:58207 CAPLUS
DOCUMENT NUMBER: 142:156197
TITLE: Preparation of 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups for use in pharmaceutical compositions as topoisomerase-I inhibitors
INVENTOR(S): Giannini, Giuseppe; Penco, Sergio; Tinti, Maria Ornella; Pisano, Claudio; Vesci, Loredana; Merlini, Lucio; Zunino, Franco
PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.P.A., Italy; Istituto Nazionale Per Lo Studio E La Cura Dei Tumori
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005431	A2	20050120	WO 2004-IT374	20040706
WO 2005005431	A3	20050224		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IT 2003-RM344 A 20030714
OTHER SOURCE(S): MARPAT 142:156197
GI



I

AB Camptothecin derivs., such as I [X = NR; R = N-protected-aminoalkyl, N-protected-aminoalkoxy, N-protected-polyaminoalkyl, N-protected-polyaminoalkoxy], which are characterized by the presence of polyamine substituents on the imine/oxime residue, such amine groups being in turn protected by suitable protective groups, were prepared for therapeutic use as topoisomerase I inhibitors. These camptothecins are claimed for use as agents for the treatment of tumors and viral and parasite infections. Thus, camptothecin derivative ST 2544 I [X = :N(CH2)3N(CO2CMe3)(CH2)4N(CO2CMe3)(CH2)3NHCO2CMe3] was prepared via an imidation reaction with 81% yield of 7-formylcamptothecin I (X = :O)with the corresponding BOC-protected

spermine derivative, H2N(CH2)3N(CO2CMe3)(CH2)4N(CO2CMe3)(CH2)3NHCO2CMe3, using Yb(OSO2CF3)3 in CH2Cl2. The prepared camptothecin derivs. were assayed for cytotoxic effect on Saccharomyces cervisiae cells and for antitumor activity against MKN-28 human gastric carcinoma.

IT **84017-99-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 7-polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups with topoisomerase-I inhibiting activity for use in pharmaceutical compns. as anticancer, antiviral and antiparasitic agents)

RN 84017-99-2 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 11-(dimethoxymethyl)-4-ethyl-4-hydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:972081 CAPLUS
DOCUMENT NUMBER: 140:27971
TITLE: Preparation of camptothecins with a modified lactone ring
INVENTOR(S): Marzi, Mauro; Marastoni, Elena; Penco, Sergio; Pisano, Claudio; Tinti, Maria Ornella; Vesci, Loredana; Zunino, Franco
PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy; Istituto Nazionale per lo Studio e la Cura dei Tumori
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101995	A2	20031211	WO 2003-IT328	20030528
WO 2003101995	A3	20040219		
WO 2003101995	C1	20041223		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2485201		AA	20031211	CA 2003-2485201	20030528
BR 2003011329		A	20050222	BR 2003-11329	20030528
EP 1511752		A2	20050309	EP 2003-730480	20030528
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011333		A	20050315	BR 2003-11333	20030528
US 2005154003		A1	20050714	US 2003-511724	20030528
JP 2005531602		T2	20051020	JP 2004-509686	20030528
PRIORITY APPLN. INFO.:				IT 2002-RM305 A	20020531
				WO 2003-IT328 W	20030528

OTHER SOURCE(S): CASREACT 140:27971; MARPAT 140:27971
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The modified camptothecins I and II (R1 = H, CR5:NOR4, R4 = H, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic group, heterocycloalkyl, aroyl, arylsulfonyl, glycosyl residue, etc.; R5 = H, alkyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl; R2, R3 = H, HO, alkoxy; n = 1,2; Z = H, alkyl) their racemic mixts., their individual enantiomers, their individual diastereoisomers, their mixts., and their pharmaceutically acceptable salts were prepared as topoisomerase I inhibitors. Thus, the intermediate III, prepared in 4 steps from camptothecin, was treated with tert-BuONH2.HCl sheltered from light at 80° for 16 h to give R,S-7-(1-tert-butoxyiminomethyl)homocamptothec in (ST2127) II (R = CH:NOCMe3, R1 = R2 = H) (IV). The IC50 of IV against non-microcytomal lung cancer cell line was 0.026 μM.

IT **84017-99-2P**, ST 2337
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of camptothecins with a modified lactone ring as topoisomerase I inhibitors)

RN 84017-99-2 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 11-(dimethoxymethyl)-4-ethyl-4-hydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:106563 CAPLUS
DOCUMENT NUMBER: 116:106563
TITLE: Chemical modification of an antitumor alkaloid

camptothecin: synthesis and antitumor activity of 7-C-substituted camptothecins

AUTHOR(S): Sawada, Seigo; Nokata, Kenichiro; Furuta, Tomio; Yokokura, Teruo; Miyasaki, Tadashi

CORPORATE SOURCE: Yakult Cent. Inst. Microbiol. Res., Kunitachi, 186, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1991), 39(10), 2574-80
CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 116:106563

GI



I

AB A radical substitution reaction of 20(S)-camptothecin (I, R = H) with methanol furnished 7-hydroxymethylcamptothecin I (R = CH2OH). Reaction of I (R = H) with primary alcs. higher than methanol gave 7-alkylcamptothecins I (R = hydroxyalkyl). For the preparation of 7-alkylcamptothecin I (R = alkyl), aldehydes were used as a radical source and several alkylated derivs. were synthesized. 7-Acyloxymethyl derivs., 7-carbaldehyde, iminomethyl derivs., acid, esters and amides were synthesized starting from I (R = CH2OH). 7-Ethyl- and 7-propylcamptothecin, acyloxymethyl compds. and Et ester exhibited higher antitumor activity than I (R = H) against L1210 in mice.

IT **84017-99-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antitumor activity of)

RN 84017-99-2 CAPLUS

CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 11-(dimethoxymethyl)-4-ethyl-4-hydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ACCESSION NUMBER: 1983:54274 CAPLUS
DOCUMENT NUMBER: 98:54274
TITLE: 7-Substituted camptothecin derivatives
INVENTOR(S): Miyasaka, Tadashi; Mutai, Masahiko; Sawada, Seigo; Nokata, Kenichiro
PATENT ASSIGNEE(S): Yakult Honsha Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 56692	A1	19820728	EP 1982-300104	19820108
EP 56692	B1	19850814		
R: BE, CH, DE, FR, GB, IT, SE				
JP 57116075	A2	19820719	JP 1981-1148	19810109
JP 62047191	B4	19871006		
JP 57116076	A2	19820719	JP 1981-1149	19810109
JP 62047192	B4	19871006		
JP 57185285	A2	19821115	JP 1981-67594	19810507
JP 62047189	B4	19871006		
US 4399276	A	19830816	US 1981-336494	19811231
CA 1177487	A1	19841106	CA 1982-393558	19820104

PRIORITY APPLN. INFO.:
JP 1981-1148 A 19810109
JP 1981-1149 A 19810109
JP 1981-67594 A 19810507

OTHER SOURCE(S): CASREACT 98:54274
GI



I

AB 7-Substituted camptothecins I [R = CHO, CH2OR1, CH(OR1)2, [R1 = C1-6-alkyl or Ph(CH2)1-3], CH:NOH or CH:NNR2R3 (R2, R3 = H, C1-6-alkyl, aryl, CONH2, acyl, aminoalkyl or amidino, or R2R3N = heterocyclyl)], which have anti-tumor activity (no data), were prepared from I (R = CH2OH) (II). Thus, 100 mg II dissolved in 50 mL pyridine and 50 mL DMF was treated with 200 mg PhCH2COCl for 6 h at 90-100° to give 56.5% I (R = CH2O2CCH2Ph) and 19.1% I (R = CHO).

IT **84017-99-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 84017-99-2 CAPLUS
CN 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 11-(dimethoxymethyl)-4-ethyl-4-hydroxy-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 09:31:56 ON 01 NOV 2005)

FILE 'REGISTRY' ENTERED AT 09:32:07 ON 01 NOV 2005
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 1 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:32:44 ON 01 NOV 2005
L4 4 S L3

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO

Structure attributes must be viewed using STN Express query preparation.

=>

=> d ibib abs hitstr 1-65

L4 ANSWER 1 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:904323 CAPLUS
DOCUMENT NUMBER: 143:241966
TITLE: Combination of a cyclooxygenase 2 (COX-2) inhibitor and a DNA topoisomerase 1 inhibitor for treatment of neoplasia
INVENTOR(S): Masferrer, Jaime L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 65 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005187172	A1	20050825	US 2004-22174	20041223
PRIORITY APPLN. INFO.:			US 2003-532203P P	20031223

AB The invention provides combinations of a Cox-2 inhibitor (e.g. celecoxib; preparation described) and a DNA topoisomerase inhibitor and methods of use thereof for preventing and/or treating neoplasia or or a neoplasia-related disorder in a subject.

IT **220997-99-9**, BN-80927
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase 2 inhibitor combination with DNA topoisomerase 1 inhibitor for treatment of neoplasia)

RN 220997-99-9 CAPLUS

CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methyl-12-[(4-methyl-1-piperidinyl)methyl]-, monohydrochloride, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

L4 ANSWER 2 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:888946 CAPLUS

10/511,724

Inventor

L4 ANSWER 25 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:972081 CAPLUS
DOCUMENT NUMBER: 140:27971
TITLE: Preparation of camptothecins with a modified lactone ring
INVENTOR(S): Marzi, Mauro; Marastoni, Elena; Penco, Sergio; Pisano, Claudio; Tinti, Maria Ornella; Vesci, Loredana; Zunino, Franco
PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy; Istituto Nazionale per lo Studio e la Cura dei Tumori
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101995	A2	20031211	WO 2003-IT328	20030528
WO 2003101995	A3	20040219		
WO 2003101995	C1	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2485201	AA	20031211	CA 2003-2485201	20030528
BR 2003011329	A	20050222	BR 2003-11329	20030528
EP 1511752	A2	20050309	EP 2003-730480	20030528
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011333	A	20050315	BR 2003-11333	20030528
US 2005154003	A1	20050714	US 2003-511724	20030528
JP 2005531602	T2	20051020	JP 2004-509686	20030528

PRIORITY APPLN. INFO.: IT 2002-RM305 A 20020531
WO 2003-IT328 W 20030528

OTHER SOURCE(S): CASREACT 140:27971; MARPAT 140:27971
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The modified camptothecins I and II (R1 = H, CR5:NOR4, R4 = H, alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclic group, heterocycloalkyl, aroyl, arylsulfonyl, glycosyl residue, etc.; R5 = H, alkyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl; R2, R3 = H, HO, alkoxy; n = 1,2; Z = H, alkyl) their racemic mixts., their individual enantiomers, their individual diastereoisomers, their mixts., and their pharmaceutically acceptable salts were prepared as topoisomerase I inhibitors. Thus, the intermediate III, prepared in 4 steps from camptothecin, was treated with tert-BuONH2.HCl sheltered from light at 80° for 16 h to give R,S-7-(1-tert-butoxyiminomethyl)homocamptothec in (ST2127) II (R = CH:NOCMe3, R1 = R2 = H) (IV). The IC50 of IV against non-microcytomal lung cancer cell line was 0.026 μM.

IT **631870-07-0P 631870-09-2P 631870-10-5P**
631870-12-7P 631870-14-9P 631870-16-1P
631870-17-2P 631870-18-3P 631870-19-4P
631870-20-7P 631870-21-8P 631870-22-9P
631870-24-1P 631870-26-3P 631870-27-4P
631870-28-5P 631870-29-6P 631870-30-9P
631870-32-1P 631870-33-2P 631870-34-3P
631870-35-4P 631870-36-5P 631870-37-6P
631870-38-7P 631870-39-8P 631870-40-1P
631870-41-2P 631870-42-3P 631870-43-4P
631870-44-5P 631870-45-6P 631870-46-7P
631870-47-8P 632356-55-9P, ST 2127 **632356-56-0P**
, ST 2143 **632356-58-2P**, (-)-ST 2127
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of camptothecins with a modified lactone ring as topoisomerase I inhibitors)

RN 631870-07-0 CAPLUS
CN 1H,3H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-12-carboxaldehyde, 5-ethyl-4,5,13,15-tetrahydro-5-hydroxy-3,15-dioxo-, 12-(O-methyloxime) (9CI) (CA INDEX NAME)



RN 631870-09-2 CAPLUS
CN 1H,3H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-12-carboxaldehyde, 5-ethyl-4,5,13,15-tetrahydro-5-hydroxy-3,15-dioxo-, 12-(O-ethyloxime) (9CI) (CA INDEX NAME)



RN 631870-10-5 CAPLUS
CN 1H,3H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-12-carboxaldehyde, 5-ethyl-4,5,13,15-tetrahydro-5-hydroxy-3,15-dioxo-, 12-[O-(1-methylethyl)oxime] (9CI) (CA INDEX NAME)



RN 632356-56-0 CAPLUS
CN 1H,3H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-12-carboxaldehyde, 5-ethyl-4,5,13,15-tetrahydro-5-hydroxy-3,15-dioxo-, 12-[O-(phenylmethoxy)oxime] (9CI) (CA INDEX NAME)



RN 632356-58-2 CAPLUS
CN 1H,3H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-12-carboxaldehyde, 5-ethyl-4,5,13,15-tetrahydro-5-hydroxy-3,15-dioxo-, 12-[O-(1,1-dimethylethyl)oxime], [C(E),5S]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



L4 ANSWER 26 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:971853 CAPLUS
DOCUMENT NUMBER: 140:16850



L4 ANSWER 63 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:479535 CAPLUS
DOCUMENT NUMBER: 129:109247
TITLE: Preparation and formulation of camptothecin analogs as prodrugs for use as antitumor, antiviral, and parasiticidal agents
INVENTOR(S): Bigg, Dennis; Lavergne, Olivier; Harnett, Jerry; Rolland, Alain; Liberatore, Anne-Marie; Lanco, Christophe; et al.
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828304	A1	19980702	WO 1997-FR2217	19971205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2757515	A1	19980626	FR 1996-15775	19961220
FR 2757515	B1	20000505		
CA 2275345	AA	19980702	CA 1997-2275345	19971205
AU 9853264	A1	19980717	AU 1998-53264	19971205
AU 734512	B2	20010614		
EP 946566	A1	19991006	EP 1997-950235	19971205
EP 946566	B1	20031105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1241192	A	20000112	CN 1997-180816	19971205
CN 1090634	B	20020911		
BR 9713977	A	20000411	BR 1997-13977	19971205
NZ 335938	A	20000428	NZ 1997-335938	19971205
JP 2001506270	T2	20010515	JP 1998-528447	19971205
JP 3576174	B2	20041013		
RU 2190613	C2	20021010	RU 1999-115884	19971205
AT 253582	E	20031115	AT 1997-950235	19971205
PT 946566	T	20040331	PT 1997-950235	19971205
ES 2206760	T3	20040516	ES 1997-950235	19971205

PL 188109	B1	20041231	PL 1997-334092		19971205
ZA 9711270	A	19980623	ZA 1997-11270		19971215
TW 410224	B	20001101	TW 1997-86119342		19971219
US 6339091	B1	20020115	US 1999-332520		19990614
NO 9902997	A	19990818	NO 1999-2997		19990618
HK 1024694	A1	20030502	HK 2000-104033		20000704
US 6797715	B1	20040928	US 2000-612382		20000707
US 2002160994	A1	20021031	US 2002-61049		20020130
US 6762301	B2	20040713			
US 2003004150	A1	20030102	US 2002-71046		20020206
US 6815546	B2	20041109			
US 2005038064	A1	20050217	US 2004-930622		20040831
PRIORITY APPLN. INFO.:			FR 1996-15775	A	19961220
			FR 1996-15945	A	19961224
			GB 1995-12670	A	19950621
			WO 1996-FR980	W	19960621
			FR 1996-15774	A	19961220
			FR 1997-10785	A	19970829
			US 1997-973561	A2	19971202
			WO 1997-FR2217	W	19971205
			WO 1997-FR2218	W	19971205
			WO 1998-FR1768	W	19980807
			FR 1999-2398	A	19990226
			US 1999-332520	A3	19990614
			WO 2000-FR461	W	20000224
			US 2000-612382	A3	20000707
			US 2001-806952	W	20010405
			US 2002-71046	A3	20020206

OTHER SOURCE(S): MARPAT 129:109247
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Camptothecin analogs I [R1 = alkyl, alkenyl, alkynyl, haloalkyl, etc.; R2 = R3 = R4 = R5 = H, CN, NO2, NHNH2, N3, halo, cyanoalkyl, nitroalkyl, etc.; R16 = H, acyloxy; R17 = alkoxy, amino, etc.; R18 = R19 = H, OH, halo, alkyl, alkoxy; R20 = H, halo; R21 = H, acyl, etc.; R16R17 = bond] were prepared and formulated as prodrugs for use as antitumor, antiviral, and parasiticidal agents. Thus, camptothecin analog II.HCl was prepared starting from 2-chloro-4-propionylpyridine, N-(tert-butyloxycarbonyl)glycine, and 3,4-difloroacetanilide via formation of intermediate alc. III and lactone IV, subsequent condensation of the alc. III with the amide moiety of IV, and intramol. cyclocondensation of the resulting chloride. The prepared compds. were tested for topoisomerase inhibitory activity.

IT **186668-40-6P 186668-44-0P 186668-65-5P**
186668-68-8P 186668-69-9P 186668-70-2P
186668-72-4P 186668-73-5P 186668-74-6P
186668-75-7P 186668-77-9P 186668-79-1P
186668-90-6P 186668-94-0P 209909-06-8P
209909-08-0P 209909-09-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and formulation of camptothecin analogs as prodrugs for use as antitumor, antiviral, and parasiticidal agents)

RN 186668-40-6 CAPLUS

CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-44-0 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5,12-diethyl-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-65-5 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5,10-dihydroxy- (9CI) (CA INDEX NAME)



RN 186668-68-8 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy-10-methoxy- (9CI) (CA INDEX NAME)



RN 186668-69-9 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methyl- (9CI) (CA INDEX NAME)



RN 186668-70-2 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-72-4 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methoxy- (9CI) (CA INDEX NAME)



RN 186668-73-5 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methoxy- (9CI) (CA INDEX NAME)



RN 186668-74-6 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9,11-dichloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-75-7 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy-10-methyl- (9CI) (CA INDEX NAME)



RN 186668-77-9 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-10-fluoro-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-79-1 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 10-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-90-6 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5,12-diethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy-10-methoxy- (9CI) (CA INDEX NAME)



RN 186668-94-0 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-12-methyl- (9CI) (CA INDEX NAME)



RN 209909-06-8 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9-chloro-5-ethyl-10-fluoro-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 209909-08-0 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy-10-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 209909-09-1 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9-fluoro-1,4,5,13-tetrahydro-5,10-dihydroxy- (9CI) (CA INDEX NAME)



IT **186668-63-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation and formulation of camptothecin analogs as prodrugs for use as antitumor, antiviral, and parasiticidal agents)
RN 186668-63-3 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-(phenylmethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 64 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:633920 CAPLUS
DOCUMENT NUMBER: 127:331621

TITLE: BN 80245: an E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities

AUTHOR(S): Lavergne, Olivier; Lesueur-Ginot, Laurence; Rodas, Francesc Pla; Bigg, Dennis C. H.
CORPORATE SOURCE: Inst. Henri Beaufour, Les Ulis, F-91966, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (1997), 7(17), 2235-2238
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

GI



I

AB The crucial E-ring of camptothecin was modified to afford the homologous β-hydroxylactone derivative BN 80245 (I). This compound, which is more stable than camptothecin, remains a potent inhibitor of both cell growth and topoisomerase I.

IT **186668-40-6P**, BN 80245
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of BN 80245, an E-ring modified camptothecin, with potent antiproliferative and topoisomerase I inhibitory activities)

RN 186668-40-6 CAPLUS

CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 65 OF 65 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:140288 CAPLUS
DOCUMENT NUMBER: 126:144433
TITLE: Preparation of novel camptothecin analogs as antitumor agents
INVENTOR(S): Bigg, Dennis; Lavergne, Olivier; Pla, Rodas Francesc; Pommier, Jacques; Ulibarri, Gerard
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'application, Fr.; Bigg, Dennis; Lavergne, Olivier; Pla Rodas, Francesc; Pommier, Jacques; Ulibarri, Gerard
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9700876	A1	19970109	WO 1996-FR980	19960621
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
CA 2225528	AA	19970109	CA 1996-2225528	19960621
AU 9664608	A1	19970122	AU 1996-64608	19960621
AU 716377	B2	20000224		
ZA 9605318	A	19970124	ZA 1996-5318	19960621
EP 835258	A1	19980415	EP 1996-924010	19960621
EP 835258	B1	20020925		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, LT, LV, FI				
CN 1192740	A	19980909	CN 1996-196127	19960621
CN 1114608	B	20030716		
BR 9608639	A	19990629	BR 1996-8639	19960621
JP 11508249	T2	19990721	JP 1997-503644	19960621
JP 3576171	B2	20041013		
NZ 312715	A	20000128	NZ 1996-312715	19960621
RU 2164515	C2	20010327	RU 1998-101135	19960621
IL 128044	A1	20010430	IL 1996-128044	19960621
IL 122635	A1	20011031	IL 1996-122635	19960621
RO 117918	B1	20020930	RO 1997-2400	19960621
AT 224900	E	20021015	AT 1996-924010	19960621
EP 1251125	A2	20021023	EP 2002-77736	19960621
EP 1251125	A3	20021211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI, CY, TR, BG, CZ, EE, SK					
PT 835258	T	20030228	PT 1996-924010		19960621
ES 2184882	T3	20030416	ES 1996-924010		19960621
PL 185354	B1	20030430	PL 1996-324339		19960621
TW 457234	B	20011001	TW 1996-85109645		19960808
US 5981542	A	19991109	US 1997-973561		19971202
NO 9705988	A	19980219	NO 1997-5988		19971219
NO 316749	B1	20040426			
HK 1015783	A1	20040319	HK 1999-100955		19990309
US 6313135	B1	20011106	US 1999-325913		19990604
US 6339091	B1	20020115	US 1999-332520		19990614
US 6797715	B1	20040928	US 2000-612382		20000707
US 2002160994	A1	20021031	US 2002-61049		20020130
US 6762301	B2	20040713			
US 2003004150	A1	20030102	US 2002-71046		20020206
US 6815546	B2	20041109			
CN 1432571	A	20030730	CN 2002-150454		20021113
JP 2004123756	A2	20040422	JP 2003-395824		20031126
US 2004254163	A1	20041216	US 2004-862245		20040607
US 2005038064	A1	20050217	US 2004-930622		20040831
PRIORITY APPLN. INFO.:			GB 1995-12670	A	19950621
			US 1996-610476	A	19960304
			EP 1996-924010	A3	19960621
			IL 1996-122635	A3	19960621
			JP 1997-503644	A3	19960621
			WO 1996-FR980	W	19960621
			FR 1996-15774	A	19961220
			FR 1996-15775	A	19961220
			FR 1996-15945	A	19961224
			FR 1997-10785	A	19970829
			US 1997-973561	A1	19971202
			WO 1997-FR2217	W	19971205
			WO 1997-FR2218	W	19971205
			WO 1998-FR1768	W	19980807
			FR 1999-2398	A	19990226
			US 1999-332520	A3	19990614
			WO 2000-FR461	W	20000224
			US 2000-612382	A3	20000707
			US 2001-806952	W	20010405
			US 2002-71046	A3	20020206

OTHER SOURCE(S): MARPAT 126:144433
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A camptothecin analogs I and II (R1 = alkyl, alkenyl, alkynyl, alkoxy, alkylthio; R2, R3, R4 R5 = independently, H, halo, alkyl, cyano, azido, hydrazino, heterocyclic substituted alkyl or acyl; R16 = H, alkoxy; R17 = alkoxy, amino, heterocyclic amino; R18, R19 = independently, H, halo, OH, alkyl, alkoxy; R20 = H, halo) were prepared by a variety of synthetic paths and were tested for topoisomerase I inhibiting activity as antitumor agents. Thus, camptothecin analog III was prepared form 7-ethylcamptothecin and reduced topoisomerase I activity to 96.9% at 10 μM and 20.4% at 500 μM of control activity levels. Camptothecin analog III was also tested against various tumor cell lines such as L1210 and HCT15.

IT **186668-40-6P 186668-44-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of camptothecin analogs as antitumor agents)

RN 186668-40-6 CAPLUS

CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-44-0 CAPLUS

CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5,12-diethyl-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



IT **186668-63-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of camptothecin analogs as antitumor agents)

RN 186668-63-3 CAPLUS

CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-(phenylmethoxy)- (9CI) (CA INDEX NAME)



IT **186668-66-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of camptothecin analogs as antitumor agents)

RN 186668-66-6 CAPLUS

CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione,

11-[(dimethylamino)methyl]-5-ethyl-1,4,5,13-tetrahydro-5,10-dihydroxy- (9CI) (CA INDEX NAME)



IT **186668-65-5P 186668-67-7P 186668-68-8P**
186668-69-9P 186668-70-2P 186668-72-4P
186668-73-5P 186668-74-6P 186668-75-7P
186668-77-9P 186668-79-1P 186668-81-5P
186668-83-7P 186668-90-6P 186668-94-0P
186669-03-4P 186669-04-5P 186669-06-7P
186669-07-8P 186669-08-9P 186669-09-0P
186669-10-3P 186669-12-5P 186669-13-6P
186669-14-7P 186669-18-1P 186669-19-2P
186669-20-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of camptothecin analogs as antitumor agents)

RN 186668-65-5 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5,10-dihydroxy- (9CI) (CA INDEX NAME)



RN 186668-67-7 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 11-[(dimethylamino)methyl]-5-ethyl-1,4,5,13-tetrahydro-5,10-dihydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 186668-68-8 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy-10-methoxy- (9CI) (CA INDEX NAME)



RN 186668-69-9 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methyl- (9CI) (CA INDEX NAME)



RN 186668-70-2 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-72-4 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methoxy- (9CI) (CA INDEX NAME)



RN 186668-73-5 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methoxy- (9CI) (CA INDEX NAME)



RN 186668-74-6 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9,11-dichloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-75-7 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy-10-methyl- (9CI) (CA INDEX NAME)



RN 186668-77-9 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-10-fluoro-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-79-1 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 10-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-81-5 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 10-chloro-5-ethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy- (9CI) (CA INDEX NAME)



RN 186668-83-7 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5,10-dihydroxy-11-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 186668-90-6 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5,12-diethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy-10-methoxy- (9CI) (CA INDEX NAME)



RN 186668-94-0 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-12-methyl- (9CI) (CA INDEX NAME)



RN 186669-03-4 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methoxy-12-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 186669-04-5 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9-chloro-5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-10-methoxy-12-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 186669-06-7 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-12-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 186669-07-8 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-12-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 186669-08-9 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-12-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 186669-09-0 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-10-fluoro-1,4,5,13-tetrahydro-5-hydroxy-12-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 186669-10-3 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-10-fluoro-1,4,5,13-tetrahydro-5-hydroxy-12-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 186669-12-5 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy-12-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 186669-13-6 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy-12-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 186669-14-7 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-9-fluoro-1,4,5,13-tetrahydro-5-hydroxy-12-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 186669-18-1 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 9-chloro-5-ethyl-10-fluoro-1,4,5,13-tetrahydro-5-hydroxy-12-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 186669-19-2 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 186669-20-5 CAPLUS
CN 3H,15H-Oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione, 5-ethyl-1,4,5,13-tetrahydro-5-hydroxy-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 09:41:56 ON 01 NOV 2005)

```
     FILE 'REGISTRY' ENTERED AT 09:42:01 ON 01 NOV 2005
L1                STRUCTURE UPLOADED
L2             15 S L1
L3            391 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 09:43:11 ON 01 NOV 2005
L4             65 S L3

=> d l1
L1 HAS NO ANSWERS
L1                STR
```



G1 H,OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s-BuO,t-BuO

Structure attributes must be viewed using STN Express query preparation.

=>